Skip to content
OpenCapital
Get started

Regeneron Pharmaceuticals REGN Cash & Equivalents

Cash & Equivalents at other companies

Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Amgen logo
AmgenAMGN
$559M+10.0%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$35.73M+109%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%
Glaukos logo
GlaukosGKOS
$104.25M-8.8%
EyePoint, Inc. logo
EyePoint, Inc. EYPT
$77.71M-8.7%

Other financials

Income statement

See full
Revenue$3.6B+19.0%
Operating income$642.9M+8.7%
Net income$727.2M-10.1%
EPS (diluted)$6.75-7.2%

Balance sheet

See full
Total debt$2.7B+0.1%
Total equity$31.4B+6.9%
Total assets$40.9B+8.9%

Cash flow

See full
Operating cash flow$1.1B+3.2%
CapEx$230.6M+0.6%
Free cash flow$848.3M+4.0%

Valuation

See full
Market cap$65.01B+18.1%
Enterprise value$64.75B+18.5%
P/E14.7×+2.5×
P/S4.4×+0.5×

Profitability

See full
Gross margin93.9%—
Operating margin24.3%-2.9pp
Net margin29.6%-2.3pp
FCF margin27.6%+5.5pp

Returns & leverage

See full
Return on equity14.5%-1.4pp
Debt / equity0.1×0.0×
Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regeneron Pharmaceuticals's cash & equivalents?
Regeneron Pharmaceuticals (REGN) reported cash & equivalents of $2.97B in Q1 2026.
How has Regeneron Pharmaceuticals's cash & equivalents changed year-over-year?
Regeneron Pharmaceuticals's cash & equivalents decreased by 4.0% year-over-year, from $3.09B to $2.97B.
What is the long-term trend for Regeneron Pharmaceuticals's cash & equivalents?
Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's cash & equivalents has grown at a 7.2% compound annual growth rate (CAGR), from $2.21B to $3.12B.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.